This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (11)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Stuart L. Fine, MD

Arch Ophthalmol. 1984;102(9):1282-1285.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In recent years, ophthalmologists have grown accustomed to clinical trials that demonstrate therapeutic benefit. The first major eye trial in recent years was the Diabetic Retinopathy Study,¹ which reported in 1976 that scatter laser photocoagulation was effective in reducing the risk of loss of vision in eyes with proliferative retinopathy. In 1982, the Macular Photocoagulation Study (MPS) Group² announced that prompt argon laser photocoagulation of neovascular membranes (NVMs) outside the foveal avascular zone (FAZ) reduced the risk of severe loss of vision in patients with age-related macular degeneration (AMD).

See also p 1299.

In 1983, the MPS Group³ reported similar findings for treatment of eyes with ocular histoplasmosis and new vessels outside the FAZ. Also in 1983, the Proliferative Sickle Cell Retinopathy Trial⁴ reported that feeder vessel photocoagulation reduced the incidence of vitreous hemorrhage and subsequent loss of vision, and the Central Serous Chorioretinopathy Trial⁵ . . . [Full Text PDF of this Article]

Author Affiliations
Baltimore

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?